Jefferies Financial Group Initiates Coverage on Genmab A/S (NASDAQ:GMAB)

Equities researchers at Jefferies Financial Group initiated coverage on shares of Genmab A/S (NASDAQ:GMAB) in a note issued to investors on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $41.50 price target on the stock. Jefferies Financial Group’s target price points to a potential upside of 42.32% from the stock’s current price.

Several other research analysts have also recently weighed in on GMAB. HC Wainwright reaffirmed a “buy” rating and set a $39.00 target price on shares of Genmab A/S in a research note on Wednesday, January 28th. Wall Street Zen lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Morgan Stanley initiated coverage on shares of Genmab A/S in a report on Monday. They issued an “equal weight” rating and a $34.00 target price on the stock. Zacks Research cut shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Finally, Truist Financial restated a “buy” rating and issued a $48.00 price target (down previously from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.30.

Genmab A/S Trading Down 2.8%

Shares of NASDAQ:GMAB opened at $29.16 on Tuesday. The company has a 50 day moving average of $32.25 and a 200-day moving average of $29.87. The firm has a market cap of $18.73 billion, a P/E ratio of 18.81, a P/E/G ratio of 17.61 and a beta of 0.90. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $35.43.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Tuesday, February 17th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.41). The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. Genmab A/S had a return on equity of 17.67% and a net margin of 25.89%. Equities research analysts forecast that Genmab A/S will post 1.45 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Hedge funds have recently bought and sold shares of the business. Federated Hermes Inc. bought a new position in Genmab A/S during the third quarter valued at approximately $12,972,000. JPMorgan Chase & Co. increased its stake in shares of Genmab A/S by 17.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock worth $19,282,000 after purchasing an additional 135,814 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its stake in shares of Genmab A/S by 24.1% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 315,862 shares of the company’s stock valued at $9,687,000 after purchasing an additional 61,311 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in Genmab A/S by 636.3% in the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock worth $1,947,000 after purchasing an additional 81,434 shares in the last quarter. Finally, Eagle Global Advisors LLC increased its position in Genmab A/S by 16.3% during the third quarter. Eagle Global Advisors LLC now owns 244,470 shares of the company’s stock worth $7,498,000 after buying an additional 34,175 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S News Roundup

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Company announced a targeted share buy‑back to cover Restricted Stock Unit obligations (repurchase of up to 342,130 shares, max ~725m DKK), which reduces float and is typically supportive of the share price. Genmab Announces Initiation of Share Buy‑Back Program
• Positive Sentiment: Multiple broker actions: HC Wainwright raised its price target to $40 (buy), Jefferies started coverage with a $41.50 buy rating, and Morgan Stanley began coverage — all represent fresh institutional support and higher PTs versus current levels. HC Wainwright PT raise / coverage reports
• Positive Sentiment: Earnings/IR materials highlighted strong revenue growth and strategic expansion initiatives, which investors can view as positive for medium‑term fundamentals even though EPS missed (see negative item). Q4 2025 Earnings Highlights
• Neutral Sentiment: Genmab published its 2025 Annual Report and filed Form 20‑F with the U.S. SEC — useful for diligence and visibility into guidance/backlog but not an immediate price mover by itself. Genmab Publishes 2025 Annual Report Genmab Files Form 20‑F
• Neutral Sentiment: Company summoned its Annual General Meeting for March 19, 2026 (routine governance event; may include board elections shown in the notice). AGM Notice
• Negative Sentiment: Genmab missed Q4 EPS expectations — reported EPS was below consensus (company’s EPS print came in under analyst estimates), which is the primary near‑term negative catalyst pressuring the stock despite revenue roughly in line. Q4 2025 Earnings Report / Transcript

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.